EMEA-001220-PIP05-19 - paediatric investigation plan
Baricitinib
PIPHuman
Eli Lilly & Company Limited
Tel. +44 (0)1276 483000
E-mail: eu_paediatric@lilly.com
P/0070/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for baricitinib (Olumiant) (EMEA-001220-PIP05-19)